290-87-9

应用筛选条件

关键词:'290-87-9'

显示 1-10 #N/A 922 条结果关于 "290-87-9" 范围网站内容

Merck Invests € 290 Million in U.S. Drug Safety Testing Capacity

Merck invests more than € 290 million in its biosafety testing capacity at Rockville, Maryland, USA.

X-tremeGENE™ 9 DNA Transfection Reagent Protocol

Plate cells approx. 24 hours before transfection making sure cells are at optimal concentration (70 – 90 % confluency).

CRISPR Cas 9 Nuclease RNA-guided Genome Editing

Learn about CRISPR Cas9, what it is and how it works. CRISPR is a new, affordable genome editing tool enabling access to genome editing for all.

Color Determination of sugar based on ICUMSA Color GS2-9

Learn about the ICUMSA® Method GS2-9 (2024) to measure the color of sample solutions of white sugar or highly pure sugar syrup of color index up to 600 IU.

X-tremeGENE™ 9 DNA转染试剂实验方案

约转染前24小时接种细胞，确保细胞处于最佳密度（7090 %融合度）。

Merck Opens New €290 Million Biosafety Testing Facility in Rockville, Maryland, USA

Merck has opened its new €290 million biosafety testing facility in Rockville, Maryland, USA.

Merck Expands in Gillingham, UK, Boosts Distribution Capabilities

Merck today announced the completion of a £9 million expansion to its Gillingham distribution center.

Pressure-Temperature Calculator for Solvents

Use the calculator to determine the boiling point or pressure of solvents based on the Antoine Equation and see solvent attributes. View a list of products based on the solvent CAS number.

Reducing the Need for Animal Testing for Biological Reactivity in Polymer Characterization

This page provides an overview of USP , , and , compares bioreactivity testing, and describes the transition of our organization towards in vitro test methods.

Accelerated mAb Development Program – From Transfection to GMP Drug Substance in 9 Months

The accelerated mAb development program delivers GMP drug substance nine months from transfection. We designed the mAbExpress™ program to be fast, cost effective, and appropriate for the early clinical phase of your program, with regulatory support throughout.

1/93